ACT Genomics, a Taiwan-based cancer molecular information company, has raised US$12.5 million series B funding led by Hotung Group and CDIB Capital Management, according to a company announcement. Existing investors Eminent II VC, Hua Nan Venture Capital, President International Development and UMC Capital also participated in the round. ACT Genomics is providing comprehensive genomic profiling […]
Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.
Visit the original source and full text: China Money Network
Any news and links syndicated from other sources are copyright those respective websites and/or publications. We post brief synopsis and links per what the respective websites' RSS feeds provide.